

HR 5663

TREAT Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 21, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 22, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/5663>

Sponsor

Name: Rep. Harshbarger, Diana [R-TN-1]

Party: Republican • **State:** TN • **Chamber:** House

Cosponsors (24 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Babin, Brian [R-TX-36]	R · TX		Oct 21, 2021
Rep. Burchett, Tim [R-TN-2]	R · TN		Oct 21, 2021
Rep. Cammack, Kat [R-FL-3]	R · FL		Oct 21, 2021
Rep. DesJarlais, Scott [R-TN-4]	R · TN		Oct 21, 2021
Rep. Donalds, Byron [R-FL-19]	R · FL		Oct 21, 2021
Rep. Fleischmann, Charles J. "Chuck" [R-TN-3]	R · TN		Oct 21, 2021
Rep. Gohmert, Louie [R-TX-1]	R · TX		Oct 21, 2021
Rep. Jackson, Ronny [R-TX-13]	R · TX		Oct 21, 2021
Rep. Mast, Brian J. [R-FL-18]	R · FL		Oct 21, 2021
Rep. Miller-Meeks, Mariannette [R-IA-2]	R · IA		Oct 21, 2021
Rep. Perry, Scott [R-PA-10]	R · PA		Oct 21, 2021
Rep. Posey, Bill [R-FL-8]	R · FL		Oct 21, 2021
Rep. Rose, John W. [R-TN-6]	R · TN		Oct 21, 2021
Rep. Roy, Chip [R-TX-21]	R · TX		Oct 21, 2021
Rep. Scott, Austin [R-GA-8]	R · GA		Oct 21, 2021
Rep. Steube, W. Gregory [R-FL-17]	R · FL		Oct 21, 2021
Rep. Williams, Roger [R-TX-25]	R · TX		Oct 21, 2021
Rep. Moore, Barry [R-AL-2]	R · AL		Oct 22, 2021
Rep. Tenney, Claudia [R-NY-22]	R · NY		Oct 28, 2021
Rep. Boebert, Lauren [R-CO-3]	R · CO		Nov 5, 2021
Rep. Grothman, Glenn [R-WI-6]	R · WI		Jan 10, 2022
Rep. Rutherford, John H. [R-FL-4]	R · FL		Jan 11, 2022
Rep. Letlow, Julia [R-LA-5]	R · LA		Jan 13, 2022
Rep. Fallon, Pat [R-TX-4]	R · TX		Feb 2, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 22, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Oct 21, 2021)

Treatment Restoration for Emergency Antibody Therapeutics Act or the TREAT Act

This bill prohibits the Department of Health and Human Services (HHS) from implementing any policy that restricts health care facilities from ordering and receiving COVID-19 monoclonal antibody therapies directly from manufacturers and distributors. In addition, the bill expressly nullifies a policy announced on September 13, 2021, under which HHS allocated supplies of these therapies through state or territorial governments.

Actions Timeline

- **Oct 22, 2021:** Referred to the Subcommittee on Health.
- **Oct 21, 2021:** Introduced in House
- **Oct 21, 2021:** Referred to the House Committee on Energy and Commerce.